SCHEMBL2989222

SCHEMBL2989222

CCOC(=O)C(CC)CCCCCCCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 2/20 0.50
FFAR4 Q5NUL3 2/20 0.49
FFAR1 O14842 2/20 0.49
ALDH1A1 P00352 3/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
GPR84 Q9NQS5 7/20 0.45
PPARG P37231 7/20 0.45
PPARD Q03181 7/20 0.45
PPARA Q07869 7/20 0.45
HDAC11 Q96DB2 5/20 0.45
TSHR P16473 4/20 0.45
PTPN1 P18031 3/20 0.45
TLR2 O60603 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
FABP4 P15090 2/20 0.45
SLC22A6 Q4U2R8 1/20 0.45
SLC22A8 Q8TCC7 1/20 0.45
MEN1 O00255 1/20 0.45
ESR1 P03372 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11648993 1.00 CPB2 (0.50) CPB2FFAR4FFAR1ALDH1A1CA1
SCHEMBL14809730 1.00 CPB2 (0.50) CPB2FFAR4FFAR1ALDH1A1CA1
SCHEMBL14810123 1.00 CPB2 (0.50) CPB2FFAR4FFAR1ALDH1A1CA1
SCHEMBL14809719 1.00 CPB2 (0.50) CPB2FFAR4FFAR1ALDH1A1CA1
SCHEMBL14809034 1.00 CPB2 (0.50) CPB2FFAR4FFAR1ALDH1A1CA1
SCHEMBL8744261 1.00 CPB2 (0.50) CPB2FFAR4FFAR1ALDH1A1CA1
SCHEMBL14809849 1.00 CPB2 (0.50) CPB2FFAR4FFAR1ALDH1A1CA1
SCHEMBL14809348 1.00 CPB2 (0.50) CPB2FFAR4FFAR1ALDH1A1CA1
SCHEMBL14810075 1.00 CPB2 (0.50) CPB2FFAR4FFAR1ALDH1A1CA1
SCHEMBL4113412 0.93 CA2 (0.48) CPB2FFAR4FFAR1ALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250152533-A1 Novel Beta-Alanine Compositions and Methods of Use Thereof LEGACY CORPORATE LENDING, LLC, AS ADMINISTRATIVE AGENT 2025-05-15 US disclosed
EP-1741767-B2 Process for the manufacture of diesel range hydrocarbons NESTE OYJ (FI) 2023-04-05 EP disclosed
EP-1681337-B2 Method for the manufacture of hydrocarbons NESTE OIL OYJ (FI) 2020-05-13 EP disclosed
CN-107530270-A Cosmetics and the concentrate for preparing the cosmetics GCT有限公司 2018-01-02 CN disclosed
EP-2990462-A1 PROCESS FOR THE MANUFACTURE OF DIESEL RANGE HYDROCARBONS Neste Oil Oyj (FI) 2016-03-02 EP disclosed
EP-2918660-A1 Process for low-hydrogen-consumption conversion of renewable feedstocks to alkanes Energy & Environmental Research Center Foundation (US) 2015-09-16 EP disclosed
EP-1741767-B1 Process for the manufacture of diesel range hydrocarbons NESTE OIL OYJ (FI) 2015-07-22 EP disclosed
US-20140275670-A1 PROCESS FOR LOW-HYDROGEN-CONSUMPTION CONVERSION OF RENEWABLE FEEDSTOCKS TO ALKANES UNITED STATES DEPARTMENT OF ENERGY 2014-09-18 US disclosed
US-8278492-B2 Process for the manufacture of diesel range hydrocarbons NESTE OIL OYJ (FI) 2012-10-02 US disclosed
EP-1681337-B1 Method for the manufacture of hydrocarbons NESTE OIL OYJ (FI) 2010-12-01 EP disclosed
US-7781124-B2 Hologram recording material NITTO DENKO CORPORATION (JP) 2010-08-24 US disclosed
EP-2040685-A2 SUSTAINED-RELEASE ALCOHOL-RESISTANT MULTIMICROPARTICULATE ORAL PHARMACEUTICAL FORM COMPRISING ANTI-MISUSE MEANS Flamel Technologies (FR) 2009-04-01 EP disclosed
US-7491858-B2 Method for the manufacture of hydrocarbons FORTUM OYJ (FI) 2009-02-17 US disclosed
US-20080305404-A1 Which can vary refractive index upon irradiation with visible light laser and exhibits an excellent transparency after the modulation without requiring any conventional complicated procedure; syndiotactic acrylic ester polymer with side chain vinyl group, and specific photopolymerization initiator NITTO DENKO CORPORATION (JP) 2008-12-11 US disclosed
WO-2007135193-A2 SUSTAINED-RELEASE ALCOHOL-RESISTANT MULTIMICROPARTICULATE ORAL PHARMACEUTICAL FORM COMPRISING ANTI-MISUSE MEANS FLAMEL TECHNOLOGIES (FR) 2007-11-29 WO disclosed
WO-2007003708-A1 PROCESS FOR THE MANUFACTURE OF DIESEL RANGE HYDROCARBONS NESTE OIL OYJ (FI) 2007-01-11 WO disclosed
EP-1741767-A1 Process for the manufacture of diesel range hydrocarbons Neste Oil OYJ (FI) 2007-01-10 EP disclosed
US-20060161032-A1 Plant, animal fats and oils converted to diesel fuel by decarboxylation/decarbonylation by heterogeneous elemental transition metal catalysts pre-treated with hydrogen on suports of metal oxides, mesoporous materials, carbonaceous structures; decreased hydrogen consumption FORTUM OYJ (FI) 2006-07-20 US disclosed
WO-2006075057-A2 METHOD FOR THE MANUFACTURE OF HYDROCARBONS NESTE OIL OYJ (FI) 2006-07-20 WO disclosed
EP-1681337-A1 Method for the manufacture of hydrocarbons Neste Oil OYJ (FI) 2006-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250152533-A1 Novel Beta-Alanine Compositions and Methods of Use Thereof GYS1, PYGM, AADAT CPB2 212/4885FFAR4 2139/4885FFAR1 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.